Patents Examined by Taeyoon Kim
  • Patent number: 10889792
    Abstract: A method includes introducing a suspension including cells suspended in a cell culture medium through a feed port or a drain port into a cavity of a cell culture vessel, the suspension being in an amount sufficient to cover a gas permeable, liquid impermeable membrane positioned at a bottom of the cell culture vessel, the feed port being disposed through a surface of the cell culture vessel and configured to permit additional cell culture medium into the cavity, and the drain port being disposed through the surface of the cell culture vessel and configured to permit removal of the cells, cell culture medium, and used cell culture medium from the cavity, allowing the cells to settle on the gas permeable, liquid impermeable membrane by gravity, removing the used cell culture medium through the drain port and introducing the additional cell culture medium through the feed port such that a constant volume is maintained in the cell culture vessel until the cells expand to a desired cell density, wherein the removi
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: January 12, 2021
    Assignee: Global Life Sciences Solutions USA LLC
    Inventors: Weston Blaine Griffin, Xiaohua Zhang, Reginald Donovan Smith, Vandana Keskar
  • Patent number: 10876105
    Abstract: Disclosed is a method for the isolation of extracellular vesicles, including exosomes, from a liquid sample, the method comprising the steps of: adjusting the pH of a liquid sample comprising extracellular vesicles to a preselected, binding pH; contacting the liquid sample with silicon carbide, wherein at the preselected, binding pH, the extracellular vesicles bind to the silicon carbide; and eluting the bound extracellular vesicles from the silicon carbide. The liquid samples can comprise bodily fluids. Further disclosed is a method for producing a liquid sample, substantially depleted of extracellular vesicles, including exosomes.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: December 29, 2020
    Assignee: Norgen Biotek Corp.
    Inventor: Yousef Haj-Ahmad
  • Patent number: 10870834
    Abstract: A method of generating a nephrospheroid is disclosed. The method comprises culturing human adult kidney cells in a culture medium under non-adherent conditions. Uses thereof and other renal cell populations are also disclosed.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: December 22, 2020
    Assignees: TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD., RAMOT AT TEL-AVIV UNIVERSITY LTD.
    Inventors: Benjamin Dekel, Orit Harari-Steinberg, Ella Buzhor
  • Patent number: 10858627
    Abstract: Disclosed is a method to differentiate stern, progenitor or precursor cells comprising contacting said stem, progenitor or precursor cells with miR-130a, or an RNA having at least 95% identity thereto, so as to yield cells of endothelial lineage. Further disclosed are compositions comprising the endothelial lineage cells obtained and methods of using the compositions for treating diseases including cardiovascular diseases.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: December 8, 2020
    Assignee: Regents of the University of Minnesota
    Inventors: Daniel J. Garry, Naoko Koyano-Nakagawa, Mary G. Garry, Bhairab Singh
  • Patent number: 10858643
    Abstract: An approach for preparing a vaccine using ultraviolet radiation is described. Aspects of this approach involve multiple iterations of inactivation of the vaccine using an ultraviolet radiation source at a set of different wavelengths and dosages. A recognition test of the vaccine using the set of different wavelengths and dosages is performed after the multiple iterations of inactivation. A controller compares results from the inactivation test and the recognition test to determine an area of acceptable radiation dosages and wavelengths generated from the ultraviolet radiation source that irradiate the live organisms without affecting efficacy and safety of the vaccine. The area of acceptable ultraviolet radiation dosages and wavelengths is representative of a difference between an ultraviolet radiation dosage that is required for inactivation and an ultraviolet radiation dosage that leads to a loss of recognition.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: December 8, 2020
    Assignee: Sensor Electronic Technology, Inc.
    Inventors: Alexander Dobrinsky, Michael Shur
  • Patent number: 10851404
    Abstract: Luciferin-containing substrates are provided including a substrate and luciferin dried on the substrate. The luciferin-containing substrate is free of a detectable amount of reactive luciferase. The substrate is optionally a nonwoven substrate. Monitoring devices are also provided. The monitoring devices include a test element having a test portion, a detection reagent comprising luciferase, a luciferin-containing substrate, and a container having a first end with an opening and a second end opposite the first end. The container is configured to receive the test portion and configured to be operationally coupled to an analytical instrument. The detection reagent and the luciferin each are capable of participating in one or more chemical reaction that results in the formation of a detectable product.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: December 1, 2020
    Assignee: 3M Innovative Properties Company
    Inventors: Hongying Jiang, Masayuki Nakamura, Xuan Jiang, Catherine A. Bothof
  • Patent number: 10845359
    Abstract: The present invention relates to a method for analyzing the activation state of a signaling pathway in a cell or tissue separated from a subject through real time single molecule protein-protein interaction analysis, and a method for selecting a personalized medicine or predicting a therapeutic efficacy to a medicine using the same.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: November 24, 2020
    Assignee: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Tae-Young Yoon, Hong Won Lee
  • Patent number: 10837002
    Abstract: The present disclosure relates to: an artificial peritoneal tissue comprising a cellular tissue and a mesothelial cell layer that covers the surface of the cellular tissue, wherein the cellular tissue comprises a fibroblast, an extracellular matrix, and a vascular endothelial cell and/or a lymphatic endothelial cell each capable of forming a lumen; and a method for producing the artificial peritoneal tissue.
    Type: Grant
    Filed: August 25, 2015
    Date of Patent: November 17, 2020
    Assignees: HIROSAKI UNIVERSITY, OSAKA UNIVERSITY
    Inventors: Hiroshi Shimoda, Yoshiya Asano, Mitsuru Akashi, Michiya Matsusaki
  • Patent number: 10821206
    Abstract: Method of the osteoreparative processes' correction and/or bone defect restoration by means of human cell-based products (cell and/or tissue transplants) and the method of its manufacturing. The invention a creates and establishes conditions for osteoreparative processes restoration in destroyed bone tissue by osteoreparation cell sources restoration as the result of use cell technologies and bone tissue engineering methods, e.g. scaffold-guided regeneration, particularly by means of cell transplantation by injection and/or transplantation of original three-dimensional osteoreparative prevascularized graft (3D-OPG). Manufacturing of medical products and preparations of the product based on human cells (cell and/or tissue transplants) is dedicated for impaired osteoreparative processes correction and/or bone defect restoration.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: November 3, 2020
    Assignee: ILAYA USA CORPORATION
    Inventors: Volodymyr Mykhaylovych Oksymets, Dmytro Oleksandrovych Zubov, Roman Hennadiyovych Vasyliev
  • Patent number: 10787688
    Abstract: The invention provides a process for the preparation of hydrocarbons substituted with at least one group containing at least one oxygen atom, comprising the process steps A) reaction of a carbon source comprising at least one selected from CO2 and CO to give acetate and/or ethanol with a first microorganism, B) separating off of the acetate from the first microorganism, C) reaction of the acetate to give a hydrocarbon substituted with at least one group containing at least one oxygen atom with a second microorganism and optionally D) purification of the hydrocarbon substituted with at least one group containing at least one oxygen atom.
    Type: Grant
    Filed: May 8, 2013
    Date of Patent: September 29, 2020
    Assignee: Evonik Operations GmbH
    Inventors: Thomas Haas, Eva Maria Wittmann
  • Patent number: 10782291
    Abstract: A microbe-specific medium, containing specific chromogenic substrates, for the detection of vancomycin-resistant enterococci in a biological sample, whereby both the detection and identification of vancomycin-resistant enterococci at the species level is achieved utilizing one sample and one test.
    Type: Grant
    Filed: December 18, 2007
    Date of Patent: September 22, 2020
    Assignee: BECTON DICKINSON AND COMPANY
    Inventors: Susan Kircher, Jon E. Salomon, Sheryl Douglas-Mckay
  • Patent number: 10780135
    Abstract: A composition of probiotics is provided which promotes weight loss and maintenance thereof. More particularly, a probiotic mixture of Lactobacillus gasseri, Lactobacillus fermentum, and Lactobacillus rhamnosus are provided to reduce body adiposity, decrease inflammation of adipose tissue, and enhance metabolism in optional combination with prebiotics and excipients such as flow agents and binders. A method of administering the probiotic composition to an individual user is also provided.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: September 22, 2020
    Inventor: Hooman M. Melamed
  • Patent number: 10780130
    Abstract: The present invention relates to an epithelial stem/progenitor cell population isolated from the amniotic membrane of umbilical cord, the epithelial stem/progenitor cell population having the capacity to differentiate in multiple cell types. The invention also relates to a pharmaceutical composition comprising such an epithelial stem/progenitor cell population or a cellular extract thereof.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: September 22, 2020
    Assignee: CELLRESEARCH CORPORATION PTE LTD.
    Inventors: Toan Thang Phan, Ivor Jiun Lim
  • Patent number: 10774307
    Abstract: The present invention discloses a method of inducing and differentiating human skin-derived precursors into corneal endothelial-like cells. The present invention utilizes human skin-derived precursors to induce corneal endothelial-like cells that are theoretically close to normal human corneal endothelial cells successfully by co-culturing with B4G12 corneal endothelial cells. Furthermore, the obtained corneal endothelial-like cells are applied to a corneal endothelial decompensation animal model, and corneal endothelium of the animal is successfully repaired, which has an important clinical application prospect.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: September 15, 2020
    Inventor: Xinyi Wu
  • Patent number: 10752884
    Abstract: The disclosure relates to a method of producing induced beta cells from urine-derived cells, the method comprising providing urine-derived cells; inducing the urine-derived cells by culturing said urine-derived cells in a primary induction culture medium comprising an effective amount of at least one small molecule reprogramming factor(s) for a first period of time to obtain induced endoderm cells; inducing the induced endoderm cells by culturing said induced endoderm cells in a secondary induction culture medium comprising an effective amount of at least one small molecule reprogramming factor(s) for a second period of time to obtain induced pancreatic precursor cells; and inducing the induced pancreatic precursor cells by culturing said pancreatic precursor cells in a tertiary induction culture medium comprising an effective amount of at least one small molecule reprogramming factor(s) for a third period of time to obtain induced beta cells.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: August 25, 2020
    Assignee: University of South Australia
    Inventors: Yanchuang Han, Xin-Fu Zhou, WooKyung Kim, JunYong Yang, JiHee Kim
  • Patent number: 10745642
    Abstract: Provided herein are methods of recovering oil from microorganisms. The methods are useful, for example, in obtaining nutritional oils and/or lipid biofuels. The methods of recovering oil described herein include contacting a population of microorganisms with one or more enzymes under conditions that cause disruption of the microorganisms, concentrating the disrupted microorganisms, and extracting lipids from the disrupted microorganisms at high temperature in the presence of a salt and in the absence of solvent.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: August 18, 2020
    Assignee: MARA Renewables Corporation
    Inventors: Dorothy A. Dennis, Roberto E. Armenta
  • Patent number: 10729813
    Abstract: Provided are methods for preparing gelled, solubilized extracellular matrix (ECM) compositions useful as cell growth scaffolds. Also provided are compositions prepared according to the methods as well as uses for the compositions. In one embodiment a device, such as a prosthesis, is provided which comprises an inorganic matrix into which the gelled, solubilized ECM is dispersed to facilitate in-growth of cells into the ECM and thus adaptation and/or attachment of the device to a patient.
    Type: Grant
    Filed: October 4, 2019
    Date of Patent: August 4, 2020
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Stephen F. Badylak, Donald Freytes
  • Patent number: 10724000
    Abstract: This application relates to a method for differentiating somatic cells into multi-competent neural crest cells based on linked steps of chemically defined medium inductions. Neural crest cells are able to differentiate into numerous cell types like Schwann cells, chondrocytes, smooth muscle cells or adipocytes.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: July 28, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Martin Graf, Roberto Iacone, Eva Christina Thoma
  • Patent number: 10716836
    Abstract: Described herein are methods and compositions for the treatment and monitoring the progress of autoimmune diseases. In some embodiments, the methods include the stimulation of regulatory T cells specific to autoantigens associated with the autoimmune disease. A specific embodiment relates to diabetes mellitus, and the prevention or delay of loss of residual ?-cell mass, providing a longer remission period and delaying the onset of diabetes related, progressive, complications through immunotherapeutic induction of regulatory T cells specific for human insulin B chain. In addition, the methods described herein can be used to predict whether a subject, e.g., a subject with ongoing anti-insulin autoimmunity, will progress to T1DM, and to evaluate a subject's response to a therapeutic intervention.
    Type: Grant
    Filed: October 27, 2008
    Date of Patent: July 21, 2020
    Assignees: Joslin Diabetes Center Inc., Mercia Pharma, Inc.
    Inventors: Tihamer Orban, Peter Blackburn
  • Patent number: 10709787
    Abstract: The present invention relates to a composition comprising hydrogels from functionalized hyaluronic acid derivatives, said hydrogels loaded with exogenous enzymes selected in the group consisting of prolyl endopeptidase (PEP) and endoprotease (EP) intended for the oral treatment of celiac disease. Specifically, this invention concerns a one-pot methodology useful to prepare methacrylic derivatives of hyaluronic acid, through the formation of a specific active group on hydroxyl groups of hyaluronic acid, the subsequent substitution of the inserted active group with ethylenediamine and finally, the reaction with methacrylic anhydride. The obtained methacrylic hyaluronic acid derivatives are used to prepare hydrogels through irradiation and loaded with exogenous enzymes selected in the group consisting of prolyl endopeptidase (PEP) and endoprotease (EP). The ability of prepared hydrogels to allow the enzyme release, as active form in simulated gastrointestinal fluids is proved.
    Type: Grant
    Filed: May 6, 2015
    Date of Patent: July 14, 2020
    Assignee: NEMYSIS LIMITED
    Inventors: Giovanna Pitarresi, Fabio Salvatore Palumbo, Gaetano Giammona